Bank of America Corp DE grew its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 376.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,273,442 shares of the company's stock after buying an additional 3,376,446 shares during the quarter. Bank of America Corp DE owned 6.04% of Ventyx Biosciences worth $9,359,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets acquired a new stake in Ventyx Biosciences in the 4th quarter valued at about $276,000. Northern Trust Corp lifted its holdings in shares of Ventyx Biosciences by 4.3% in the fourth quarter. Northern Trust Corp now owns 485,664 shares of the company's stock valued at $1,064,000 after purchasing an additional 19,982 shares in the last quarter. Boothbay Fund Management LLC lifted its holdings in shares of Ventyx Biosciences by 472.2% in the fourth quarter. Boothbay Fund Management LLC now owns 314,891 shares of the company's stock valued at $690,000 after purchasing an additional 259,863 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Ventyx Biosciences in the fourth quarter valued at approximately $436,000. Finally, MetLife Investment Management LLC increased its stake in shares of Ventyx Biosciences by 76.0% during the 4th quarter. MetLife Investment Management LLC now owns 26,731 shares of the company's stock worth $59,000 after purchasing an additional 11,543 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company's stock.
Ventyx Biosciences Stock Up 2.3%
Shares of Ventyx Biosciences stock traded up $0.04 during trading on Thursday, hitting $1.81. 682,358 shares of the company were exchanged, compared to its average volume of 1,337,330. Ventyx Biosciences, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $5.66. The firm has a 50 day moving average price of $1.24 and a 200 day moving average price of $1.73. The stock has a market capitalization of $128.80 million, a price-to-earnings ratio of -0.77 and a beta of 0.73.
Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.09. Analysts predict that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.
Ventyx Biosciences Profile
(
Free Report)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
See Also
Before you consider Ventyx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.
While Ventyx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
